[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients will be randomized to the following 3 groups.1) Group with 150mg/dayIn addition to ordinary therapyies for COVID-19; the study drug 150 mg/day will be administered to patients for 14 days.2) Group with 300mg/dayIn addition to ordinary therapyies for COVID-19; the study drug 300 mg/day (150mg for one dose; 2 times per day) will be administered to patients for 14 days.3) Control group Patients will receive only ordinary therapies for COVID-19 as doctors indicated.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "150mg day for 14 days", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "300mg day for 14 days", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients will be randomized to the following 3 groups.1) Group with 150mg/dayIn addition to ordinary therapyies the study drug 150 mg/day will be administered to patients for 14 days.2) Group with 300mg/dayIn addition to ordinary therapyies; the study drug 300 mg/day (150mg for one dose; 2 times per day) will be administered to patients for 14 days.3) Control group Patients will receive only ordinary therapies as doctoters indicated.BAT: best available therapy", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients will be randomized to the following 3 groups.1) Group with 150mg/dayIn addition to ordinary drug therapyies the study drug 150 mg/day will be administered to patients for 14 days.2) Group with 300mg/dayIn addition to ordinary drug therapyies; the study drug 300 mg/day (150mg for one dose; 2 times per day) will be administered to patients for 14 days.3) Control group Patients will receive only ordinary drug therapies as doctoters indicated.BAT: best available therapy", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Patients will be randomized to the following 3 groups.1) Group with 150mg/dayIn addition to BAT (Favipiravir) administration for 10 days (Max 14 days); the study drug 150 mg/day will be administered to patients for 14 days.2) Group with 300mg/dayIn addition to BAT (Favipiravir) administration for 10 days (Max 14 days); the study drug 300 mg/day (150mg for one dose; 2 times per day) will be administered to patients for 14 days.3) Control group (only BAT [Favipiravir]) Patients will receive only BAT for 10 days (Max14 days). BAT: best available therapy", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]